Almac Group has brought online a second stream for high throughput GMP peptide manufacturing. The new facility, based in Edinburgh, Scotland, manufactures neoantigen derived peptides for use in the production of patient specific, individualized cancer vaccines.
 
Almac has been active in high throughput manufacturing of neoantigen derived peptides—branded by Almac as NeoPeptides—for several years. The NeoPeptides facility underwent a conversion from non GMP to GMP through 2018 and has been operating in full GMP mode since September. The facility has undergone a successful MHRA inspection and has now moved into routine GMP supply. The company says demand for its NeoPeptides is growing strongly and, in response, the company has moved quickly to bring online a second GMP manufacturing line.
 
“Almac’s decision to bring a second GMP NeoPeptides manufacturing stream online so quickly after the first is a clear statement of our commitment to the field of individualized cancer vaccines,” said Charles Shields, vice president peptides and small molecule API, Almac. “We understand this market well and intend to maintain our world leading supply position on neoantigen derived peptides. We will be announcing further expansions of our facility and our service offering in the coming months.”